CD155 is the fifth member in the nectin-like molecule family, and functions as the receptor of poliovirus; therefore, CD155 is also referred to as necl-5, or PVR. As an immunoglobulin-like adhesion molecule, CD155 is involved in cell motility, and natural killer and T cell-mediated immunity. CD155 is barely or weakly expressed in various normal human tissues, but frequently overexpressed in human malignant tumors. CD155 overexpression promotes tumor cell invasion and migration, and is associated with tumor progression and poor prognosis. As the ligand for both costimulatory receptor CD226 and coinhibitory receptor TIGIT and CD96 on natural killer and T cells, CD155 seems to play a dual role in oncoimmunity. However, some recent studies indicate that CD155 overexpression may induce tumor immune escape. Taken together, CD155 may be considered as a target for the treatment of tumors with CD155 overexpression. C D155 was originally identified as a poliovirus receptor (PVR), with conserved amino acids and domain structure characteristics similar to the immunoglobulin superfamily.
C D155 was originally identified as a poliovirus receptor (PVR), with conserved amino acids and domain structure characteristics similar to the immunoglobulin superfamily. (1, 2) CD155 is also referred to as necl-5, as it belongs to the nectinlike molecule family. These molecules harbor domain structures similar to nectins, which play critical roles in cell adhesion and polarization. (3) CD155 heterophilically trans-interacts with nectin-3, colocalizing to epithelial cell-cell junctions. (4, 5) CD155 overexpression promotes cell migration in a nectin-3-dependent or nectin-3-independent manner. (4, 6) Moreover, CD155 overexpression stimulates cell proliferation, and enhances growth factor-induced cell proliferation. (7) In fact, CD155 overexpression can reduce the expression of nectin-3, and disrupt contact inhibition. (8) Regulation of CD155 Expression DNA damage. DNA damage or DNA-replication inhibitors induce CD155 expression through the activation of ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) protein kinases. For instance, some chemotherapeutic agents for multiple myeloma patients can upregulate CD155 on human fibroblasts and mouse tumor cells (Fig. 1a ) (9) Moreover, reactive oxygen species and reactive nitrogen species can also stimulate CD155 expression through DNA damage response (DDR) (Fig. 1a) . (10, 11) Viruses have been extensively demonstrated to induce DDR, leading to genomic instability and the development of human cancers. (12, 13) Therefore, it is reasonable to ask whether viruses can induce CD155. However, until recently, only HIV-1 Vpr protein was reported to upregulate CD155 involving the activation of ATR kinase and DDR. (14) It remains unclear whether CD155 is involved in virus-related human cancers. Interestingly, cytomegalovirus has been observed to downregulate CD155, which is considered to be a mechanism for this virus to escape immune surveillance. (15) Ras/FGF. Transformed V12Ras-NIH3T3 cells express higher level of CD155 than wild-type NIH3T3 cells, indicating that oncogenic Ras can upregulate CD155 expression (Fig. 1b) . (4) This induction involves Raf-MEK-ERK-AP1 signaling, and fibroblast growth factor (FGF) can also upregulate CD155 expression through this signaling. (16) Sonic hedgehog signaling. The sonic hedgehog (Shh) signaling pathway plays a critical role in cell differentiation, cell proliferation and tissue polarity. Aberrant Shh-Gli activation is involved in a series of human cancers. (17, 18) CD155 expression in human Ntera2 cells can be upregulated by treatment with purified shh protein; an intact Gli binding site has been found in CD155 core promoter, which is required for CD155 upregulation (Fig. 1c) . (19) TLR4 signaling. CD155 expression on dendritic cells (DC) can be upregulated by a series of toll-like receptor (TLR) agonists, including LPS. (20, 21) This induction involves TLR adaptor molecules MYD88 and TRIF, and depends on the activation of NF-jB (Fig. 1d) . (22) In addition to DC, CD155 expression on neutrophils and macrophages can also be upregulated by LPS. (23) It is unknown whether TLR signaling in the tumor microenvironment attributes to CD155 overexpression on tumor cells. IFN-c, induced by TLR4 activation, has been shown to upregulate CD155 expression on melanoma cells. (24) Overexpression of CD155 in human malignancies CD155 expression is barely detected in most normal tissues, but upregulated in a series of human malignancies, including colon cancer, lung adenocarcinoma, melanoma, pancreatic cancer and glioblastoma. (25) (26) (27) (28) (29) Clinicopathological analysis indicates that CD155 overexpression is correlated with tumor progression and unfavorable prognosis. (26) (27) (28) Moreover, levels of soluble isoforms of CD155 in the sera of cancer patients are significantly higher than those of healthy donors, and are positively correlated with cancer stage. (30) These studies suggest that CD155 may be used as a biomarker for cancer progression and prognosis.
CD155 plays a key role in tumor cell invasion and migration. (29, 31, 32) During migration, CD155 is recruited to the leading edge of migrating tumor cells, where it is colocalized with actin and avb3 integrin. (29) CD155 overexpression reduces substrate adhesion, but enhances cell dispersal, which is dependent on the activation of Src/focal adhesion kinase (FAK) signaling. (32) CD155 also plays a positive role in tumor growth. CD155 overexpression in ras-transformed cells upregulates cyclin D2, downregulates p27 and shortens the G0/G1 phase. (33) In contrast, CD155 downregulation suppresses tumor cell proliferation and induces cell-cycle arrest at G2/M phase. (28) Moreover, CD155 expression is correlated with tumor VEGF expression and intratumoral vessel density (Fig. 2) . (28) Interaction of CD155 with CD226 in antitumor immunity Costimulatory molecule CD226 (DNAX accessory molecule-1, DNAM-1) is mainly expressed on T cells, natural killer (NK) cells, monocytes and B cells. Anti-CD226 monoclonal antibody (MAb) suppresses T and NK cell-mediated cytotoxicity against some tumor cells, whereas it has no effect on the cytolysis of others, suggesting that CD226-induced cytotoxicity depends on specific ligands from tumor cells. (34) A study using CD226-deficient mice has shown that CD226 is required for the activation of CD8 + cytotoxic T lymphocytes (CTL) by antigens from tumor cells. (20) CD155 and CD112 have been identified as the ligands for CD226. (35, 36) Interaction of CD226 with CD155/CD112 triggers NK or T cell-mediated cytotoxicity, accompanied by an increase in cytokine production. Further in vitro studies have shown that tumor cells with higher CD155 expression are more susceptible to CD226-induced killing. (37, 38) In contrast, compared with wild-type mice, CD226-deficient NK or T cells display significantly less cytotoxic activity against CD155-positive tumor cells than wild-type cells, and CD226-deficient mice show increased tumor development and mortality after transplantation of CD155-positive tumor cells. (39) Moreover, CD226 has been revealed to mediate the inhibition of CD155-positive tumor metastasis by NK cells. (40) Surprisingly, some later studies have shown that CD226 expression in the tumor microenvironment is downregulated. Peripheral blood NK (p-NK) cells and tumor-infiltrating NK (Ti-NK) cells from breast cancer patients express decreased CD226 and some other activating receptors, with weakened cytotoxicity. (41) Factors such as TGF-b1 and PGE 2 secreted by stromal cells and/or cancer cells are responsible the reduction of NK cell CD226 expression and cytotoxicity. (41) These results have also been observed in a cancer MMTV-Neu transgenic mouse model. (42) Moreover, CD226 expression is downregulated on NK cells from myeloma patients with active disease compared with patients in remission and healthy controls. (43) In addition, interaction between CD155 and CD226 can downregulate CD226 expression. (44) Similarly, CD112, another ligand for CD226, is also involved in CD226 downregulation. (45) CD226 expression on T and NK cells is increased remarkably in CD155 knockdown mice or mice treated with CD155-neutralizing antibody. (46) This regulation is post-transcriptional based on the fact that CD226 mRNA has not been affected. (46) One mechanism underlying CD226 downregulation may be related to CD155/CD112-induced CD226 internalization.
Interaction of CD155 with TIGIT in tumor immune evasion
TIGIT contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and is expressed on T cells and NK cells. Yu and colleagues found that TIGIT can bind to CD155 on DC with high affinity and suppress T cell activation indirectly by modulating DC activity. (47) Stanietsky and colleagues further demonstrate that TIGIT is a coinhibitory receptor on NK cells for CD155 and CD112. (48) Studies using TIGIT knockdown mice have revealed that TIGIT inhibits T cell proliferation and activation independent of antigen-presenting cell (APC)-derived CD155. (49) However, the intrinsic inhibitory effect of TIGIT may be still related to CD155. As shown by Lozano and colleagues, T cell-derived CD155 can bind to CD226 to activate T cells under the condition of TIGIT deficiency. (50) Moreover, TIGIT has been demonstrated to directly disrupt CD226 homodimerization, suppressing CD8 + T cell response by interfering with CD155/ CD226 interaction. (51) Contrary to CD226, TIGIT is significantly upregulated on tumor-infiltrating T cells, and its expression parallels with that of other coinhibitory receptors, most notably PD-1, indicating that TIGIT also acts as a marker of chronically stimulated or exhausted tumor-infiltrating T cells. (51) Moreover, high TIGIT expression on CD8 + T cells is associated with refractory leukemia and leukemia relapse. (52) One recent study by Inozume and colleagues has shown that CD155 overexpression in melanoma cells inhibits CTL response in the presence of CD226, and this inhibition depends on the interaction between CD155 and TIGIT. (24) It is reasonable to consider that CD155 overexpression in tumor cells may result in increased CD155 combination with coinhibitory molecules, including TIGIT. However, TIGIT blockade alone or TIGIT knockdown has no obvious effect on tumor growth and metastasis, suggesting that other inhibitory molecules may compensate for TIGIT. (51, 53) Interaction of CD155 with CD96 in tumor immune evasion CD96 was originally identified by Wang and colleagues and named as Tactile (T cell activation, increased late expression). (54) Like TIGIT, CD96 also contains an ITIM and is expressed on T cells and NK cells. By using NK92 cells, Fuchs and colleagues have revealed CD96 as another receptor for CD155, and that interaction between CD96 and CD155 mediates cell adhesion. (55) Chan et al. (2014) demonstrate that CD96 is a coinhibitory receptor on NK cells by generating CD96 knockdown mice. (23) Their study has indicated that CD96 not only competes with CD226 for CD155 binding, but also directly suppresses NK cell function via binding with CD155. CD226 knockdown mice are susceptible to melanoma lung metastasis, but CD96 knockdown mice are resistant to it. (23) CD96 blockade can further suppress melanoma metastasis in TIGIT knockdown mice. (23, 53) CD155 Ligands-Mediated Signals CD155-CD226 ligation. CD226 ligation is associated with CD226 tyrosine phosphorylation, indicating that CD226 is a signal-transducing molecule. (34) CD226-mediated adhesion and cytotoxicity by NK cells involves PKC, which phosphorylates CD226 at Ser 329 . (56) CD226 Ser 329 phosphorylation facilitates the association of CD226 with LFA-1 (CD11a/CD18), inducing CD226 tyrosine phosphorylation via fyn protein tyrosine kinase. (57) CD155-TIGIT ligation. Ligation of CD155 with TIGIT results in TIGIT phosphorylation at Tyr225, recruiting SHIP1 (SH2-containing inositol phosphatase 1) via adaptor molecule Grb2; SHIP1 further blocks phosphatidylinositol 3-kinase (PI3K) and ERK signaling, and inhibits NK cell-mediated cytotoxicity. (58) Phosphorylated TIGIT can also recruit SHIP1 via adaptor molecule b-arrestin 2, suppressing NF-jB activity and IFN-c production in NK cells. (59) These findings indicate that SHIP1 is a key molecule in CD155-TIGIT signaling (Fig. 3) . Indeed, SHIP1 silencing opposes TIGIT/CD155-mediated inhibitory signaling and restores NK cell cytotoxicity. (59) CD155-CD96 ligation. CD96 has been demonstrated to suppress NK cell function via binding with CD155; however, CD96-mediated signaling remains unknown. (23) CD155-nectin-3 ligation. Similar to interaction between nectins, interaction of CD155 with nectin-3 also induces the activation of Cdc42 and Rac, involving molecules including c-Src, Rap1, FRG and Vav2. (3, 60) As an immunoregulatory molecule, CD155 can combine with costimulatory molecule CD226, and coinhibitory molecules TIGIT and CD96, having a dual function in oncoimmunity. Accordingly, the balance between CD155/CD226 and CD155/ TIGIT or CD155/CD96 maintains normal NK and T cell function. However, this balance may be disrupted in the tumor microenvironment. On one hand, tumor cells usually overexpress CD155; on the other hand, tumor-infiltrating immune cells may express decreased CD226 and increased TIGIT. Therefore, CD155/TIGIT or CD155/CD96-mediated inhibitory signaling may be dominant in the tumor microenvironment (Fig. 4) .
Some other findings also lead us to deliberately consider the role of CD155 in human tumors, such as the overexpression of CD155 on human tumor cells, involvement of some oncogenic signaling in the regulation of CD155 expression, attribution of CD155 to tumor growth and metastasis, and correlation of CD155 expression with tumor progression and prognosis. Thus, more investigations should be undertaken to determine the effect of anti-CD155 treatment for tumors. It has been demonstrated that chemotherapeutic agents can induce CD155 expression on tumor cells. Due to the possibility that CD155 overexpression may counteract the efficiency of chemotherapeutic agents, combination of anti-CD155 therapy with chemotherapy could be considered under this condition.
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